Dr Mel Bridges  BAPPSC, FAICD Non-Executive Director Appointed 12 October 2007 Resigned 18 June 2014 

Dr Mel Bridges has more than 30 years’ experience as a CEO and public company director in the global biotechnology and healthcare industry. During this period, he founded and managed successful diagnostics, biotechnology and medical device businesses. He has successfully raised in excess of $300 million investment capital in the healthcare/biotech sector and been directly involved in over $1 billion in M&A and related transactions. 

The businesses that Dr Bridges has founded have won numerous awards including the Queensland Export Award, Australian Small Business of the Year, Queensland Top 400, BRW’s Top 100 Fastest Growing Companies for seven consecutive years and The Australian Quality Award. 

Dr Bridges has an Honorary Doctorate from Queensland University of Technology 

Other Current Directorships of Listed Companies 

ALS Ltd, Tissue Therapies Ltd. 

Former Directorships of Listed Companies in last three years 

Alchemia Limited (October 2003 to July 2013), Genetic Technologies Limited (December 2011 to November 2012), Leaf Energy Limited (August 2010 to September 2012), and Genera Biosystems Limited (December 2008 to November 2010). 

Dr Bridges retired from the Board in June 2014. 

Dr John Chiplin PH.D. Non-Executive Director Appointed 1 February 2010 

Dr. Chiplin is CEO of Polynoma LLC, an immuno-oncology company currently running one of the world’s largest (Phase III) melanoma trials. Prior to Polynoma, he was the founding CEO of Arana Therapeutics, a world leading antibody developer, and a director of Domantis, Inc., prior to their acquisition by Cephalon & GSK respectively. 

Dr Chiplin’s investment vehicle, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. Dr. Chiplin’s Pharmacy and Doctoral degrees are from the University of Nottingham. In addition to Benitec Biopharma, he currently serves on the board of ScienceMedia, Inc. and Adalta Pty.Ltd 

Other Current Directorships of Listed Companies : None 

Former Directorships of Listed Companies in the last three years Arana Therapeutics Ltd., Calzada Ltd., Healthlinx, Ltd., Progen Pharmaceuticals Ltd., and Medistem, Inc. 

Mr Iain Ross BSc, CH.D. Non-Executive Director Appointed 1 June 2010 

Mr Ross brings over 30 years’ experience in the international life sciences sector to the Board of Benitec. Following a career with Sandoz, Fisons, Hoffman La Roche and Celltech, he has undertaken and had input to a number of company turnarounds and start-ups as a board member on behalf of banks and private equity groups. He has led and participated in 4 IPOs, has direct experience of life science 

mergers and acquisitions both in the UK and USA and has raised more than £250m in the biotech sector. 

He is a Qualified Chartered Director and currently he is Chairman of Ark Therapeutics Group plc (LSE); Biomer Technology Limited and Pharminox Limited; and a non-executive director of Tissue Therapies Limited (ASX), Novogen Limited (ASX) and Anatata Lifesciences Limited. He is also Vice Chairman of the Council of Royal Holloway, University of London. 

Other Current Directorships of Listed Companies Ark Therapeutics Group plc, Tissue Therapies Limited, Novogen Limited 

Former Directorships of Listed Companies in last three years:  Coms plc 

## CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR 

Dr Peter French MBA, PH.D. Chief Executive Officer and Managing Director Appointed 26 August 2013 

Peter French is a cell and molecular biologist who has been extensively involved in both basic and clinical medical research and commercialisation of biological intellectual property. He has an MBA in Technology Management and a PhD in cell biology. Dr French is a Past President of the Australia and New Zealand Society for Cell and Developmental Biology, and represented Australia’s biological scientists on the Board of FASTS, Australia’s peak government lobbying organization for science and technology. Dr French has conducted cell and molecular research in a broad range of areas relevant to Benitec’s DNA-directed RNAi based therapeutic technology, including cancer, HIV/AIDS, neurobiology, immunology and inflammatory disease. 

He obtained his PhD in 1987 for work performed at CSIRO on the characterisation of the keratin composition of the developing wool fibre. He carried out postdoctoral research at the Children’s Medical Research Foundation, Sydney, on the role of glycoprotein expression in neuronal development. In 1989 he became Principal Scientific Officer and Manager of the Centre for Immunology, St Vincent’s Hospital, Sydney. Over the past 15 years Dr French has been extensively involved in Australia’s biotechnology industry, initially founding the stem cell company Cryosite (ASX:CTE), and then taking up leadership roles at other biotechnology companies prior to joining Benitec in 2009 as its Chief Scientific Officer. Peter was appointed Chief Executive Officer of Benitec in June 2010 and Managing Director in August 2013. 

Other Current Directorships of Listed Companies: None 

Former Directorships of Listed Companies in last three years:  None 

## COMPANY SECRETARY 

Mr Greg West CA Appointed 26 May 2011 

Mr West is a Chartered Accountant with experience in the Biotech sector. He is a Director and Audit Committee Chairman of UOWE Limited (a business arm of Wollongong University), and a Director and Audit Committee Chairman of IDP Education Pty Ltd and Education Australia Limited. He worked at PWC and has held senior finance executive roles in financial services and investment banking with Bankers Trust, Deutsche Bank, NZI, and with other financial institutions. 

